GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 08/31/23
GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGlobeNewsWire • 08/10/23
GeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/23
GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023GlobeNewsWire • 07/26/23
GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGlobeNewsWire • 07/20/23
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer ConferenceGlobeNewsWire • 07/10/23
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer ConferenceGlobeNewsWire • 06/28/23
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine InsightsGlobeNewsWire • 06/27/23
GeoVax's Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised PatientsGlobeNewsWire • 05/24/23
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific MeetingsGlobeNewsWire • 05/15/23
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/04/23
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against OrthopoxvirusesGlobeNewsWire • 04/17/23
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine CandidateGlobeNewsWire • 04/06/23
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine CongressGlobeNewsWire • 04/05/23
GeoVax to Participate at the World Vaccine Congress with Multiple PresentationsGlobeNewsWire • 03/30/23